Get your free ETF data sample from our comprehensive offerings. Start your free trial→
Help us improve your experience. Please confirm your investor type:
Compare ETFs Easily
The Ultimate ETF Comparison Tool - Try Now!
Analyze up to 5 ETFs side-by-side and gain instant insights on performance, fees, holdings, and more to make data-driven investment decisions.
371470 ETF · Mirae Asset TIGER Biotech Solactive ETF
The 371470 Exchange Traded Fund (ETF) is provided by Mirae Asset Global Investments. It is built to track an index: Solactive China Biotech Index. The 371470 ETF provides physical exposure, so by buying it you actually own parts of all the 30 underlying holdings. This share class generates a stream of income by distributing dividends.
Last update Today at 12:00 AM UTC
LIVE
CLOSED
This fund is part ofChina Blended Cap1M perf.-6.31%
Last price
â‚©8,995
1M perf.
+2.55%
1M flows
-€3.3M
AuM
€34M
E/R
0.59%
Rating
Not rated
ESG Consensus®
371470
â‚©8,995
Performance & flows
Segment for quartile rank
January 2, 2026 → April 1, 2026
Create a free account to view the flows graph
371470
â‚©8,670.36
+3.46%
China Blended Cap
-7.13%
Historic performance and flows
| 1M | 3M | 1Y | 3Y | 5Y | MTD | QTD | YTD | ||
|---|---|---|---|---|---|---|---|---|---|
| Perf. | +2.55%  | +3.46% | +28.21%  | +19.96% | -23.89%  | -1.11% | -1.11% | +2.58% | |
| Flows |
Key fund info
Segment for quartile rank
This ETF's jurisdiction country is not in your region (Europe and Middle East) ·
Main characteristics
ISIN
KR7371470006
AuM
€34M
E/R
0.59%
Replication rating
Not rated
ESG Consensus®
More details
NAV
4/1/2026
â‚©8,670.36
1D NAV change
-1.11%
Dividend policy
Replication method
Direct (Physical)
Replication model
Optimized sampling
No. of holdings
30
Inception date
12/3/2020
Jurisdiction
South Korea
Distribution
South Korea
Legal structure
Open-end Fund
Base currency
KRW
Dividend distribution
Trailing 12-month distr. yield
Distribution frequency
Last distribution
Create a free account to view dividend distribution
Classification
Investment strategy
Mirae Asset TIGER Biotech Solactive ETF is an exchange-traded fund established in South Korea. The fund aims to provide return that closely replicates the performance of the Solactive China Biotech Index (Net Total Return).
Tax optimisation
PEA
France
UK Reporting Status
United Kingdom
Create a free Trackinsight Essentials account to unlock insights
Access exclusive metrics and features to support your investment decisions.
Built for professionals: access exclusive fund metrics and selection tools in Trackinsight Enterprise.
Enterprise Fund page features include:
Legal documents
Powerful buy-list integration
Fund data exports
Advanced risk metrics
Advanced replication analysis
Advanced exposure look-through
Upload your own internal metrics
Custom data feature
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseAdvertisement
Risk profile
Segment for quartile rank
Historical risk/return profile
| 3M | 1Y | 3Y | 5Y | |
|---|---|---|---|---|
| Returns | +3.46% | +28.21% | +19.96% | -23.89% |
| Volatility | ||||
| Perf./Volatility | ||||
| Max drawdown |
Create a free account to view risk/return table
Synthetic Risk and Reward Indicator (SRRI)
UCITS
N/A
PRIIPS
N/A
More exposure metrics are available, exclusively in Trackinsight Enterprise
Exposure
Countries
China
44.66%
Cayman Islands
40.51%
USA
9.23%
Unavailable
5.60%
Sectors
Health Care
77.77%
Unavailable
22.23%
Diversification
Total weight of top 15 holdings out of 30
Top 15 holdings
Data as of February 28, 2026
WUXI BIOLOGICS (CAYMAN)
APPTEC
US07725L1026
INNOVENT BIOLOGICS INC
HENGRUI MEDI
AKESO INC
SINO BIOPHARMACEUTICAL
3SBIO INC
Create a free account to view top holdings
HANSOH PHARMACEUTICAL GROUP CO LTD
CHANGSHAN PHARMA
RAAS BLOOD
PHARMARON
CNE100005XJ7
KYG7S12M1051
GAN & LEE PHARMACEUTICALS CO LTD
Create a free account to view top holdings
More risk metrics are available, exclusively in Trackinsight Enterprise
Sustainability
Integrates ESG criteria
No
SDG
More sustainability metrics are available, exclusively in Trackinsight Enterprise
Issuer
Mirae Asset Global Investments
Mirae Asset Global Investments ID Card
Number of funds
100
Total AuM
€28.82B
Expense ratio range
0.05% - 1%
Average expense ratio
0.3878%
Top 5 funds by Mirae Asset Global Investments
| AuM | ||
|---|---|---|
396500 | Mirae Asset TIGER Fn Semiconductor TOP10 ETF | €5.33B |
133690 | Mirae Asset TIGER NASDAQ 100 ETF | €4.5B |
102110 | Mirae Asset TIGER 200 ETF | €4.07B |
381170 | Mirae Asset TIGER US Tech TOP10 INDXX ETF | €2.07B |
292150 | MIRAE ASSET TIGER TOP 10 ETF | €1.29B |
Frequently asked questions about 371470
What does Mirae Asset TIGER Biotech Solactive ETF, 371470, invest in?
371470 is a Passive ETF. This ETF provides exposure to Chinese Biotechnology Equities.
Which benchmark or index does 371470 replicate?
371470 tracks the Solactive China Biotech Index - CNY, through a optimized sampling replication method.
What is the Total Expense ratio (TER) of 371470?
371470 carries a total expense ratio (TER) of 0.59%, indicating the annual cost for holding the fund.
When was 371470 launched?
371470 was introduced to the market on December 3, 2020. It trades on South Korea
Who is the ETF issuer of 371470?
Mirae Asset TIGER Biotech Solactive ETF, 371470, is provided by Mirae Asset Global Investments. Learn more about Mirae Asset Global Investments here.
What is the current assets under management (AUM) of 371470?
371470 oversees €34M in assets as of April 1, 2026.
How has 371470 performed lately?
Based on data from April 1, 2026, 371470 returned 2.55% over the past month, 3.46% over the last three months and 2.58% year-to-date.
What are the latest inflows or outflows for 371470?
As of April 1, 2026, 371470 recorded net flows of -€3.3M over the last month and -€7.2M year-to-date.
Does 371470 distribute dividends?
371470 follows a distributing dividend policy, meaning it pays out income to investors. As of April 1, 2026, its 12-month trailing yield was 0.69%.
What are the main country or region exposures of 371470?
As of February 28, 2026, 371470 has significant geographic allocations in China, Cayman Islands and USA.
In which sector or theme does 371470 invest in?
As of February 28, 2026, 371470 focuses largely on Health Care.
How many securities does 371470 hold and how diversified is it?
As of February 28, 2026, 371470 holds 30 positions in its portfolio, with 76.73% of assets concentrated in its top 15 holdings.
What are the main positions in 371470?
As of February 28, 2026, 371470 top three holdings include WUXI BIOLOGICS (CAYMAN), APPTEC and US07725L1026.
What is the base currency of 371470?
The base currency of 371470 is KRW.
Advertisement
About Trackinsight
Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.
Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.
In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.
This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.
Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.
More about TrackinsightETF TOOLS
PLATFORM
ETF NEWS & RESEARCH
© 2014-2026 Trackinsight SA. All rights reserved.
Privacy policy | Cookie policy | | Terms of use | Imprint
Privacy policy | Cookie policy | | Terms of use | Imprint
